Upadacitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Upadacitinib comprises 191 peer-reviewed publications across 15 journals, 42 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Arthritis, Rheumatoid, Crohn Disease, Dermatitis, Atopic, and Colitis, Ulcerative. Most recent publication: Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease., J Crohns Colitis, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
    Loftus EV, Panés J, Lacerda AP, et al. · N Engl J Med · 2023
    PubMed: PMID 37224198 · NCT06780683 (EaseUpIBD) · Colitis, Ulcerative
  2. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E, Thaçi D, Pangan AL, et al. · J Allergy Clin Immunol · 2020
    PubMed: PMID 31786154 · NCT02925117 · Dermatitis, Atopic
  3. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S, Vermeire S, Zhou W, et al. · Lancet · 2022
    PubMed: PMID 35644166 · NCT06780683 (EaseUpIBD) · Colitis, Ulcerative
  4. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Blauvelt A, Teixeira HD, Simpson EL, et al. · JAMA Dermatol · 2022
    PubMed: PMID 34347860 · NCT03738397 (Heads Up) · Dermatitis, Atopic
  5. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Vermeire S, Danese S, Zhou W, et al. · Lancet Gastroenterol Hepatol · 2025
    PubMed: PMID 37683686 · NCT02819635 · Colitis, Ulcerative
  6. Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
    Panaccione R, Vermeire S, Danese S, et al. · Lancet Gastroenterol Hepatol · 2025
    PubMed: PMID 40347957 · NCT03006068 (U-ACTIVATE) · Colitis, Ulcerative
  7. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
    Mysler E, Sidiropoulos PI, Balanescu A, et al. · Ann Rheum Dis · 2026
    PubMed: PMID 41991443 · NCT05814627 (SELECT- SWITCH) · Arthritis, Rheumatoid
  8. Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index.
    Ezzedine K, Soliman AM, Camp HS, et al. · JAMA Dermatol · 2025
    PubMed: PMID 39475960 · NCT04927975 · Vitiligo

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02629159
SELECT-COMPARE
Arthritis, RheumatoidPercentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
Week 12
Adalimumab18.0 percentage of participants
Placebo6.1 percentage of participants
Upadacitinib28.7 percentage of participants
NCT02629159
SELECT-COMPARE
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Adalimumab63.0 percentage of participants
Placebo36.4 percentage of participants
Upadacitinib70.5 percentage of participants
NCT02675426
SELECT-NEXT
Arthritis, RheumatoidPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Week 12
Placebo17.2 percentage of participants
Upadacitinib 15 mg48.4 percentage of participants
Upadacitinib 30 mg47.9 percentage of participants
NCT02675426
SELECT-NEXT
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Placebo35.7 percentage of participants
Upadacitinib 15 mg63.8 percentage of participants
Upadacitinib 30 mg66.2 percentage of participants
NCT02706847
SELECT-BEYOND
Arthritis, RheumatoidPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Week 12
Placebo14.2 percentage of participants
Upadacitinib 15 mg43.3 percentage of participants
Upadacitinib 30 mg42.4 percentage of participants
NCT02706847
SELECT-BEYOND
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Placebo28.4 percentage of participants
Upadacitinib 15 mg64.6 percentage of participants
Upadacitinib 30 mg56.4 percentage of participants
NCT02706873
SELECT-EARLY
Arthritis, RheumatoidChange From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Global Analysis
Baseline to Week 24
Methotrexate0.67 units on a scale
Upadacitinib 15 mg0.14 units on a scale
Upadacitinib 30 mg0.07 units on a scale
NCT02706873
SELECT-EARLY
Arthritis, RheumatoidPercentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Global Analysis
Week 24
Methotrexate18.5 percentage of participants
Upadacitinib 15 mg48.3 percentage of participants
Upadacitinib 30 mg50.0 percentage of participants
NCT02706873
SELECT-EARLY
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 - Global Analysis
Baseline and Week 12
Methotrexate54.1 percentage of participants
Upadacitinib 15 mg75.7 percentage of participants
Upadacitinib 30 mg77.1 percentage of participants
NCT02706873
SELECT-EARLY
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global Analysis
Baseline and Week 12
Methotrexate28.3 percentage of participants
Upadacitinib 15 mg52.1 percentage of participants
Upadacitinib 30 mg56.4 percentage of participants
NCT02706951Arthritis, RheumatoidPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14
Week 14
Methotrexate19.4 percentage of participants
Upadacitinib 15 mg44.7 percentage of participants
Upadacitinib 30 mg53.0 percentage of participants
NCT02706951Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14
Baseline and week 14
Methotrexate41.2 percentage of participants
Upadacitinib 15 mg67.7 percentage of participants
Upadacitinib 30 mg71.2 percentage of participants
NCT02720523
SELECTSUNRISE
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Placebo42.9 percentage of participants
Upadacitinib 15 mg83.7 percentage of participants
Upadacitinib 30 mg80.0 percentage of participants
Upadacitinib 7.5 mg75.5 percentage of participants
NCT02819635Colitis, UlcerativeSubstudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
At Week 8
SS1: Placebo0 percentage of participants
SS1: Upadacitinib 15 mg14.3 percentage of participants
SS1: Upadacitinib 30 mg13.5 percentage of participants
SS1: Upadacitinib 45 mg21.4 percentage of participants
SS1: Upadacitinib 7.5 mg8.5 percentage of participants
NCT02819635Colitis, UlcerativeSubstudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
At Week 8
SS2: Placebo4.8 percentage of participants
SS2: Upadacitinib 45 mg26.1 percentage of participants
NCT02819635Colitis, UlcerativeSubstudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52
At Week 52
SS3: Placebo12.1 percentage of participants
SS3: UPA 15 mg42.3 percentage of participants
SS3: UPA 30 mg51.7 percentage of participants
NCT02955212Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Placebo31.4 percentage of participants
Upadacitinib 15 mg71.6 percentage of participants
NCT03086343Arthritis, RheumatoidChange From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority)
Baseline and Week 12
Abatacept-2.00 units on a scale
Upadacitinib 15 mg-2.52 units on a scale
NCT03104374
SELECT - PsA 2
ArthritisPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Placebo24.1 percentage of participants
Upadacitinib 15 mg56.9 percentage of participants
Upadacitinib 30 mg63.8 percentage of participants
NCT03104400
SELECT - PsA 1
ArthritisPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Adalimumab 40 mg65.0 percentage of participants
Placebo36.2 percentage of participants
Upadacitinib 15 mg70.6 percentage of participants
Upadacitinib 30 mg78.5 percentage of participants
NCT03345836Crohn DiseaseNumber of Participants With Adverse Events
From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)
Part 1 (Double-blind): Placebo112 Participants
Part 1 (Double-blind): Upadacitinib 45 mg221 Participants
Part 2 (Open-label): Upadacitinib 45 mg86 Participants
Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg45 Participants
Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo53 Participants
Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg9 Participants
NCT03345836Crohn DiseasePercentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12
Week 12
Part 1 (Double Blind): Placebo21.1 percentage of participants
Part 1 (Double Blind): Upadacitinib 45 mg38.9 percentage of participants
NCT03345836Crohn DiseasePercentage of Participants With Endoscopic Response at Week 12
Baseline to Week 12
Part 1 (Double Blind): Placebo3.5 percentage of participants
Part 1 (Double Blind): Upadacitinib 45 mg34.6 percentage of participants
NCT03345849
U-EXCEL
Crohn DiseasePercentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12
Week 12
Placebo29.1 percentage of participants
Upadacitinib 45 mg QD49.5 percentage of participants
NCT03345849
U-EXCEL
Crohn DiseasePercentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12
Week 12
Placebo22.2 percentage of participants
Upadacitinib 45 mg QD50.7 percentage of participants
NCT03345849
U-EXCEL
Crohn DiseasePercentage of Participants With Endoscopic Response at Week 12
Baseline and Week 12
Placebo13.1 percentage of participants
Upadacitinib 45 mg QD45.5 percentage of participants
NCT03568318
AD Up
Dermatitis, AtopicMain Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
Baseline and Week 16
Placebo + Topical Corticosteroids26.4 percentage of participants
Upadacitinib 15 mg + Topical Corticosteroids64.6 percentage of participants
Upadacitinib 30 mg + Topical Corticosteroids77.1 percentage of participants
NCT03568318
AD Up
Dermatitis, AtopicMain Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
Baseline and Week 16
Placebo + Topical Corticosteroids10.9 percentage of participants
Upadacitinib 15 mg + Topical Corticosteroids39.6 percentage of participants
Upadacitinib 30 mg + Topical Corticosteroids58.6 percentage of participants
NCT03569293
Measure Up 1
Dermatitis, AtopicMain Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
Baseline and Week 16
Placebo16.3 percentage of participants
Upadacitinib 15 mg QD69.6 percentage of participants
Upadacitinib 30 mg QD79.7 percentage of participants
NCT03569293
Measure Up 1
Dermatitis, AtopicMain Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
Baseline and Week 16
Placebo8.4 percentage of participants
Upadacitinib 15 mg QD48.1 percentage of participants
Upadacitinib 30 mg QD62.0 percentage of participants
NCT03607422Dermatitis, AtopicMain Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
Baseline and Week 16
Placebo13.3 percentage of participants
Upadacitinib 15 mg QD60.1 percentage of participants
Upadacitinib 30 mg QD72.9 percentage of participants
NCT03607422Dermatitis, AtopicMain Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
Baseline and Week 16
Placebo4.7 percentage of participants
Upadacitinib 15 mg QD38.8 percentage of participants
Upadacitinib 30 mg QD52.0 percentage of participants
NCT03653026
U-Accomplish
Colitis, UlcerativePercentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
Week 8
Placebo4.1 percentage of participants
Upadacitinib 45 mg33.5 percentage of participants
NCT03725202
SELECT-GCA
Giant Cell ArteritisPercentage of Participants Achieving Sustained Remission at Week 52
From Week 12 to Week 52
15 mg Upadacitinib + 26-week CS Taper46.4 percentage of participants
7.5 mg Upadacitinib + 26-week CS Taper41.1 percentage of participants
Placebo + 52-week CS Taper29.0 percentage of participants
NCT03738397
Heads Up
Dermatitis, AtopicPercentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16
Baseline and Week 16
Dupilumab 300 mg EOW62.6 percentage of participants
Upadacitinib 30 mg QD72.4 percentage of participants
NCT04169373
SELECT-AXIS 2
Axial SpondyloarthritisStudy 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14
Baseline and Week 14
Study 1: Placebo18.2 percentage of participants
Study 1: Upadacitinib 15 mg44.5 percentage of participants
NCT04169373
SELECT-AXIS 2
Axial SpondyloarthritisStudy 2: Percentage of Participants Achieving an ASAS40 Response at Week 14
Baseline and Week 14
Study 2: Placebo22.5 percentage of participants
Study 2: Upadacitinib 15 mg44.9 percentage of participants
NCT04195698Dermatitis, AtopicNumber of Participants With Treatment-Emergent Adverse Events
UPA/UPA arm: BL visit in Lead-In M16-046 to last dose in Long-Term Extension M19-850 (median time on follow-up is 536 days); DUPI/UPA arm: BL visit in Long-Term Extension M19-850 to last dose plus a 30-day follow-up (median time on follow-up is 399 days).
DUPI 300mg to UPA 30mg205 Participants
DUPI 300mg to UPA 30mg12 Participants
DUPI 300mg to UPA 30mg14 Participants
UPA 30mg to UPA 30mg17 Participants
UPA 30mg to UPA 30mg18 Participants
UPA 30mg to UPA 30mg223 Participants
NCT04195698Dermatitis, AtopicNumber of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)
UPA/UPA arm: BL visit in Lead-In M16-046 to last dose in Long-Term Extension M19-850 (median time on follow-up is 536 days); DUPI/UPA arm: BL visit in Long-Term Extension M19-850 to last dose plus a 30-day follow-up (median time on follow-up is 399 days).
DUPI 300mg to UPA 30mg6 Participants
DUPI 300mg to UPA 30mg0 Participants
DUPI 300mg to UPA 30mg4 Participants
DUPI 300mg to UPA 30mg19 Participants
DUPI 300mg to UPA 30mg1 Participants
DUPI 300mg to UPA 30mg0 Participants
DUPI 300mg to UPA 30mg26 Participants
DUPI 300mg to UPA 30mg31 Participants
DUPI 300mg to UPA 30mg1 Participants
DUPI 300mg to UPA 30mg0 Participants
DUPI 300mg to UPA 30mg7 Participants
DUPI 300mg to UPA 30mg0 Participants
DUPI 300mg to UPA 30mg0 Participants
DUPI 300mg to UPA 30mg7 Participants
DUPI 300mg to UPA 30mg10 Participants
DUPI 300mg to UPA 30mg0 Participants
DUPI 300mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg8 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg5 Participants
UPA 30mg to UPA 30mg1 Participants
UPA 30mg to UPA 30mg44 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg8 Participants
UPA 30mg to UPA 30mg4 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg25 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg15 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg0 Participants
UPA 30mg to UPA 30mg8 Participants
NCT04195698Dermatitis, AtopicPercentage of Participants With Potentially Clinically Important (PCI) Laboratory Values as Assessed by the Investigator
From Baseline to 30 days following last dose of study drug (Week 52)
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg1.3 percentage of participants
DUPI 300mg to UPA 30mg3.4 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg3.4 percentage of participants
DUPI 300mg to UPA 30mg0.8 percentage of participants
DUPI 300mg to UPA 30mg0.4 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0.4 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg4.2 percentage of participants
DUPI 300mg to UPA 30mg3.8 percentage of participants
DUPI 300mg to UPA 30mg8.0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg1.7 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg1.7 percentage of participants
DUPI 300mg to UPA 30mg1.3 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0.5 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0.5 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg2.5 percentage of participants
DUPI 300mg to UPA 30mg1.3 percentage of participants
DUPI 300mg to UPA 30mg0.4 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg2.9 percentage of participants
DUPI 300mg to UPA 30mg1.3 percentage of participants
DUPI 300mg to UPA 30mg0.8 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0.8 percentage of participants
UPA 30mg to UPA 30mg3.4 percentage of participants
UPA 30mg to UPA 30mg0.8 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg3.8 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg3.4 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg3.8 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg8.1 percentage of participants
UPA 30mg to UPA 30mg5.1 percentage of participants
UPA 30mg to UPA 30mg13.1 percentage of participants
UPA 30mg to UPA 30mg0.8 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0.4 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg5.1 percentage of participants
UPA 30mg to UPA 30mg0 percentage of participants
UPA 30mg to UPA 30mg5.1 percentage of participants
NCT04195698Dermatitis, AtopicPercentage of Participants With Potentially Clinically Important (PCI) Vital Sign Measurements and Physical Examination Findings as Assessed by the Investigator
From Baseline to 30 days following last dose of study drug (Week 52)
DUPI 300mg to UPA 30mg2.5 percentage of participants
DUPI 300mg to UPA 30mg0.4 percentage of participants
DUPI 300mg to UPA 30mg0.4 percentage of participants
DUPI 300mg to UPA 30mg2.1 percentage of participants
DUPI 300mg to UPA 30mg1.7 percentage of participants
DUPI 300mg to UPA 30mg0 percentage of participants
DUPI 300mg to UPA 30mg5.5 percentage of participants
DUPI 300mg to UPA 30mg22.5 percentage of participants
UPA 30mg to UPA 30mg39.0 percentage of participants
UPA 30mg to UPA 30mg4.7 percentage of participants
UPA 30mg to UPA 30mg0.8 percentage of participants
UPA 30mg to UPA 30mg5.5 percentage of participants
UPA 30mg to UPA 30mg7.6 percentage of participants
UPA 30mg to UPA 30mg1.3 percentage of participants
UPA 30mg to UPA 30mg2.1 percentage of participants
UPA 30mg to UPA 30mg9.3 percentage of participants
NCT05601882
Level Up
Dermatitis, AtopicPercentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16
Baseline and Week 16
Dupilumab (Period 1)8.9 percentage of participants
Upadacitinib (Period 1)19.9 percentage of participants

Publications by year

1995–2026: 191 publications.

1995
1
2001
1
2005
1
2006
1
2007
1
2009
2
2010
1
2011
1
2013
2
2015
2
2016
4
2017
5
2018
5
2019
5
2020
13
2021
20
2022
35
2023
27
2024
31
2025
24
2026
9

Publications by indication

Arthritis, Rheumatoid (76)

  • Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
    Ann Rheum Dis · 2026 · PMID 41991443 · NCT05814627
  • Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.
    RMD Open · 2025 · PMID 40350200 · NCT02706951
  • Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rheumatol Ther · 2025 · PMID 39031276 · NCT03086343
  • Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.
    RMD Open · 2025 · PMID 41193232 · NCT02720523
  • Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.
    RMD Open · 2024 · PMID 39053948 · NCT02706847

Crohn Disease (32)

  • Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.
    J Crohns Colitis · 2026 · PMID 41264726 · NCT03345823
  • Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.
    Clin Gastroenterol Hepatol · 2026 · PMID 40738276 · NCT03345823
  • Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.
    Clin Gastroenterol Hepatol · 2026 · PMID 41763462 · NCT03345823
  • Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
    Inflamm Bowel Dis · 2026 · PMID 41189093 · NCT03345849
  • Dual biological therapy and small molecules in pediatric inflammatory bowel disease.
    Pharmacol Res · 2026 · PMID 37748559 · NCT06520397

Dermatitis, Atopic (27)

  • Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).
    Am J Clin Dermatol · 2026 · PMID 41533220 · NCT05601882
  • Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.
    Dermatol Ther (Heidelb) · 2025 · PMID 40457140 · NCT03569293
  • Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2).
    Dermatol Ther (Heidelb) · 2025 · PMID 40658277 · NCT03607422
  • Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
    Am J Clin Dermatol · 2025 · PMID 40900410 · NCT03607422
  • Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up).
    World Allergy Organ J · 2024 · PMID 36185549 · NCT03661138

Colitis, Ulcerative (21)

  • Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Lancet Gastroenterol Hepatol · 2025 · PMID 37683686 · NCT02819635
  • Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.
    J Crohns Colitis · 2025 · PMID 40488552 · NCT02819635
  • Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
    Lancet Gastroenterol Hepatol · 2025 · PMID 40347957 · NCT03006068
  • Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis.
    Pharmacoecon Open · 2025 · PMID 37296268 · NCT02819635
  • Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review.
    J Crohns Colitis · 2025 · PMID 39886994 · NCT07472309

Arthritis (15)

  • Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
    Clin Exp Rheumatol · 2024 · PMID 37404160 · NCT03104374
  • Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.
    Rheumatology (Oxford) · 2024 · PMID 38331400 · NCT03104400
  • Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Rheumatol Ther · 2024 · PMID 38683479 · NCT03104374
  • Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
    Rheumatol Ther · 2023 · PMID 36243812 · NCT03104400
  • Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
    RMD Open · 2023 · PMID 36754548 · NCT03104374

Axial Spondyloarthritis (9)

  • Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies.
    Rheumatol Ther · 2026 · PMID 41824252 · NCT04169373
  • Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model.
    Immunology · 2025 · PMID 41039829 · NCT04169373
  • Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study.
    Arthritis Res Ther · 2025 · PMID 39905436 · NCT04169373
  • Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease.
    RMD Open · 2025 · PMID 40037923 · NCT04169373
  • Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
    Rheumatol Ther · 2024 · PMID 36820984 · NCT04169373

Publications by journal

Trial-results highlights

Clinical trials evaluated Upadacitinib for rheumatoid arthritis. In the NCT02629159 (SELECT-COMPARE) study, at Week 12, the percentage of participants achieving clinical remission based on DAS28(CRP) was 28.7% in the Upadacitinib arm, compared to 18.0% in the Adalimumab arm and 6.1% in the Placebo arm. For an American College of Rheumatology 20% (ACR20) response at Week 12 in the same study, 70.5% of participants in the Upadacitinib arm achieved this, versus 63.0% in the Adalimumab arm and 36.4% in the Placebo arm.

Other studies also assessed disease activity. In NCT02675426 (SELECT-NEXT), at Week 12, participants achieving low disease activity (LDA) based on DAS28(CRP) included 48.4% in the Upadacitinib 15 mg arm and 47.9% in the Upadacitinib 30 mg arm, compared to 17.2% in the Placebo arm. The ACR20 response at Week 12 was 63.8% for Upadacitinib 15 mg and 66.2% for Upadacitinib 30 mg, versus 35.7% for Placebo. Similarly, in NCT02706847 (SELECT-BEYOND), at Week 12, LDA based on DAS28(CRP) was achieved by 43.3% of participants in the Upadacitinib 15 mg arm and 42.4% in the Upadacitinib 30 mg arm, compared to 14.2% in the Placebo arm. The ACR20 response at Week 12 in this study was 64.6% for Upadacitinib 15 mg and 56.4% for Upadacitinib 30 mg, versus 28.4% for Placebo.

For structural damage and remission, the NCT02706873 (SELECT-EARLY) study reported changes from baseline in modified Total Sharp Score (mTSS) at Week 24. The change was 0.14 units for Upadacitinib 15 mg and 0.07 units for Upadacitinib 30 mg, compared to 0.67 units for Methotrexate. At Week 24, clinical remission based on DAS28(CRP) was achieved by 48.3% of participants in the Upadacitinib 15 mg arm and 50.0% in the Upadacitinib 30 mg arm, versus 18.5% in the Methotrexate arm. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Upadacitinib publications (191)

2026 (9 papers)

  1. Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Vermeire S, Colombel JF, Danese S, et al. · J Crohns Colitis · 2026 · Derived
    PubMed: PMID 41264726 · NCT03345823 (U-ENDURE) · Crohn Disease
  2. Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.
    Panaccione R, Regueiro M, Lee SD, et al. · Clin Gastroenterol Hepatol · 2026 · Derived
    PubMed: PMID 40738276 · NCT03345823 (U-ENDURE) · Crohn Disease
  3. Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.
    Panaccione R, Panés J, Peyrin-Biroulet L, et al. · Clin Gastroenterol Hepatol · 2026 · Derived
    PubMed: PMID 41763462 · NCT03345823 (U-ENDURE) · Crohn Disease
  4. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
    Mysler E, Sidiropoulos PI, Balanescu A, et al. · Ann Rheum Dis · 2026 · Derived
    PubMed: PMID 41991443 · NCT05814627 (SELECT- SWITCH) · Arthritis, Rheumatoid
  5. Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
    Dubinsky MC, D'Haens G, Dewit O, et al. · Inflamm Bowel Dis · 2026 · Derived
    PubMed: PMID 41189093 · NCT03345849 (U-EXCEL) · Crohn Disease
  6. Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).
    Bunick CG, Magnolo N, Moore A, et al. · Am J Clin Dermatol · 2026 · Derived
    PubMed: PMID 41533220 · NCT05601882 (Level Up) · Dermatitis, Atopic
  7. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies.
    Baraliakos X, Bessette L, de Vlam K, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41824252 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  8. Dual biological therapy and small molecules in pediatric inflammatory bowel disease.
    Penagini F, Lonoce L, Abbattista L, et al. · Pharmacol Res · 2026 · Background
    PubMed: PMID 37748559 · NCT06520397 · Crohn Disease
  9. Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis.
    Honap S, St-Pierre J, Colwill M, et al. · Clin Gastroenterol Hepatol · 2026 · Background
    PubMed: PMID 40721074 · NCT07550673

2025 (24 papers)

  1. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model.
    Zhang X, Jia L, Lin X, et al. · Immunology · 2025 · Derived
    PubMed: PMID 41039829 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  2. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Vermeire S, Danese S, Zhou W, et al. · Lancet Gastroenterol Hepatol · 2025 · Derived
    PubMed: PMID 37683686 · NCT02819635 · Colitis, Ulcerative
  3. Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study.
    Van den Bosch F, Deodhar A, Poddubnyy D, et al. · Arthritis Res Ther · 2025 · Derived
    PubMed: PMID 39905436 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  4. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.
    Smolen JS, Emery P, Rigby W, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 40350200 · NCT02706951 · Arthritis, Rheumatoid
  5. Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.
    Simpson EL, Silverberg JI, Prajapati VH, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 40457140 · NCT03569293 (Measure Up 1) · Dermatitis, Atopic
  6. Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2).
    Silverberg JI, Gooderham M, Katoh N, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 40658277 · NCT03607422 · Dermatitis, Atopic
  7. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A, Kato K, Haraoui B, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39031276 · NCT03086343 · Arthritis, Rheumatoid
  8. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.
    Passeron T, Ezzedine K, Hamzavi I, et al. · EClinicalMedicine · 2025 · Derived
    PubMed: PMID 38873632 · NCT04927975 · Vitiligo
  9. Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease.
    Panés J, Louis E, Bossuyt P, et al. · Inflamm Bowel Dis · 2025 · Derived
    PubMed: PMID 39231444 · NCT03345849 (U-EXCEL) · Crohn Disease
  10. Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.
    Panés J, Dubinsky MC, Ishiguro Y, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 40488552 · NCT02819635 · Colitis, Ulcerative
  11. Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
    Panaccione R, Vermeire S, Danese S, et al. · Lancet Gastroenterol Hepatol · 2025 · Derived
    PubMed: PMID 40347957 · NCT03006068 (U-ACTIVATE) · Colitis, Ulcerative
  12. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease.
    Navarro-Compán V, Van den Bosch F, Sampaio-Barros PD, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 40037923 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  13. Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.
    Loftus EV, D'Haens G, Louis E, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 40704669 · NCT03345823 (U-ENDURE) · Crohn Disease
  14. Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis.
    Loftus EV, Ananthakrishnan AN, Lee WJ, et al. · Pharmacoecon Open · 2025 · Derived
    PubMed: PMID 37296268 · NCT02819635 · Colitis, Ulcerative
  15. Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.
    Kameda H, Takeuchi T, Yamaoka K, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 41193232 · NCT02720523 (SELECTSUNRISE) · Arthritis, Rheumatoid
  16. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
    Irvine AD, Prajapati VH, Guttman-Yassky E, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 40900410 · NCT03607422 · Dermatitis, Atopic
  17. Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index.
    Ezzedine K, Soliman AM, Camp HS, et al. · JAMA Dermatol · 2025 · Derived
    PubMed: PMID 39475960 · NCT04927975 · Vitiligo
  18. Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
    Danese S, Sands BE, Feagan BG, et al. · Contemp Clin Trials Commun · 2025 · Derived
    PubMed: PMID 41403476 · NCT06227910 (VICTRIVA) · Crohn Disease
  19. Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.
    Colombel JF, Lacerda AP, Irving PM, et al. · Clin Gastroenterol Hepatol · 2025 · Derived
    PubMed: PMID 39326583 · NCT03345836 · Crohn Disease
  20. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
    Burmester GR, Deodhar A, Irvine AD, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40875187 · NCT03345823 (U-ENDURE) · Crohn Disease
  21. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
    Blockmans D, Penn SK, Setty AR, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40174237 · NCT03725202 (SELECT-GCA) · Giant Cell Arteritis
  22. Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review.
    Gisbert JP, Chaparro M · J Crohns Colitis · 2025 · Background
    PubMed: PMID 39886994 · NCT07472309 · Colitis, Ulcerative
  23. IBD Matchmaking: Rational Combination Therapy.
    Battat R, Chang JT, Loftus EV, et al. · Clin Gastroenterol Hepatol · 2025 · Background
    PubMed: PMID 39025253 · NCT07442045 · Colitis, Ulcerative
  24. Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.
    Alayo QA, Fenster M, Altayar O, et al. · Crohns Colitis 360 · 2025 · Background
    PubMed: PMID 35310082 · NCT06520397 · Crohn Disease

2024 (31 papers)

  1. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.
    van Vollenhoven RF, Hall S, Wells AF, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 39053948 · NCT02706847 (SELECT-BEYOND) · Arthritis, Rheumatoid
  2. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
    van Vollenhoven R, Strand V, Takeuchi T, et al. · Arthritis Res Ther · 2024 · Derived
    PubMed: PMID 39075620 · NCT02706873 (SELECT-EARLY) · Arthritis, Rheumatoid
  3. Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up).
    Tanaka T, Sasaki T, Ikeda K, et al. · World Allergy Organ J · 2024 · Derived
    PubMed: PMID 36185549 · NCT03661138 (Rising Up) · Dermatitis, Atopic
  4. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL, Prajapati VH, Leshem YA, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38696027 · NCT03607422 · Dermatitis, Atopic
  5. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI, Gooderham MJ, Paller AS, et al. · Am J Clin Dermatol · 2024 · Derived
    PubMed: PMID 38528257 · NCT03569293 (Measure Up 1) · Dermatitis, Atopic
  6. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
    Rubbert-Roth A, Kakehasi AM, Takeuchi T, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 37982966 · NCT02706873 (SELECT-EARLY) · Arthritis, Rheumatoid
  7. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
    Raine T, Ishiguro Y, Rubin DT, et al. · J Crohns Colitis · 2024 · Derived
    PubMed: PMID 37942921 · NCT03653026 (U-Accomplish) · Colitis, Ulcerative
  8. Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis.
    Qian Y, Raymundo EM, Hao S, et al. · Clin Ther · 2024 · Derived
    PubMed: PMID 39142926 · NCT03646604 · Dermatitis, Atopic
  9. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
    Peyrin-Biroulet L, Panaccione R, Louis E, et al. · Clin Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 38492904 · NCT03345849 (U-EXCEL) · Crohn Disease
  10. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
    Panaccione R, Danese S, Zhou W, et al. · Aliment Pharmacol Ther · 2024 · Derived
    PubMed: PMID 38010661 · NCT03653026 (U-Accomplish) · Colitis, Ulcerative
  11. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
    Paller AS, Mendes-Bastos P, Siegfried E, et al. · JAMA Dermatol · 2024 · Derived
    PubMed: PMID 39441580 · NCT03568318 (AD Up) · Dermatitis, Atopic
  12. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
    Navarro-Compán V, Baraliakos X, Magrey M, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 36820984 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  13. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
    Mease P, Setty A, Papp K, et al. · Clin Exp Rheumatol · 2024 · Derived
    PubMed: PMID 37404160 · NCT03104374 (SELECT - PsA 2) · Arthritis
  14. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
    Loricera J, Tofade T, Prieto-Peña D, et al. · Arthritis Res Ther · 2024 · Derived
    PubMed: PMID 38840219 · NCT03725202 (SELECT-GCA) · Giant Cell Arteritis
  15. Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study.
    Katoh N, Ikeda M, Ohya Y, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38127188 · NCT03661138 (Rising Up) · Dermatitis, Atopic
  16. Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's Disease.
    Ghosh S, Feagan BG, Parra RS, et al. · J Crohns Colitis · 2024 · Derived
    PubMed: PMID 38835235 · NCT03345849 (U-EXCEL) · Crohn Disease
  17. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
    Fleischmann R, Swierkot J, Penn SK, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 38806190 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  18. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.
    Fleischmann R, Friedman A, Drescher E, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38293957 · NCT03682705 · Arthritis, Rheumatoid
  19. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
    Fleischmann R, Blanco R, Van den Bosch F, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38498140 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  20. Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
    Colombel JF, Hisamatsu T, Atreya R, et al. · Clin Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 38492903 · NCT03345823 (U-ENDURE) · Crohn Disease
  21. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.
    Cantini F, Marchesoni A, Novelli L, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 38331400 · NCT03104400 (SELECT - PsA 1) · Arthritis
  22. Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
    Burmester GR, Van den Bosch F, Tesser J, et al. · J Rheumatol · 2024 · Derived
    PubMed: PMID 38621793 · NCT02675426 (SELECT-NEXT) · Arthritis, Rheumatoid
  23. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR, Stigler J, Rubbert-Roth A, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38683479 · NCT03104374 (SELECT - PsA 2) · Arthritis
  24. More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
    Blauvelt A, Eyerich K, Irvine AD, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39110139 · NCT03738397 (Heads Up) · Dermatitis, Atopic
  25. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.
    Baraliakos X, van der Heijde D, Sieper J, et al. · Arthritis Res Ther · 2024 · Derived
    PubMed: PMID 39533349 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  26. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A, Olbjorn C, Kolho KL, et al. · Inflamm Bowel Dis · 2024 · Background
    PubMed: PMID 37042978 · NCT06520397 · Crohn Disease
  27. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
    Singh S, Loftus EV, Limketkai BN, et al. · Gastroenterology · 2024 · Background
    PubMed: PMID 39572132 · NCT07442045 · Colitis, Ulcerative
  28. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM, Lee JC, Bond S, et al. · Lancet Gastroenterol Hepatol · 2024 · Background
    PubMed: PMID 38402895 · NCT06520397 · Crohn Disease
  29. Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?
    Horta-Baas G · Patient Relat Outcome Meas · 2024 · Background
    PubMed: PMID 35388274 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  30. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Choy MC, Li Wai Suen CFD, Con D, et al. · Lancet Gastroenterol Hepatol · 2024 · Background
    PubMed: PMID 39236736 · NCT07550673
  31. Psoriatic Synovitis: Singularity and Potential Clinical Implications.
    Celis R, Cuervo A, Ramírez J, et al. · Front Med (Lausanne) · 2024 · Background
    PubMed: PMID 30805340 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2023 (27 papers)

  1. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
    Loftus EV, Panés J, Lacerda AP, et al. · N Engl J Med · 2023 · Trial result
    PubMed: PMID 37224198 · NCT06780683 (EaseUpIBD) · Colitis, Ulcerative
  2. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.
    Thyssen JP, Thaçi D, Bieber T, et al. · J Eur Acad Dermatol Venereol · 2023 · Derived
    PubMed: PMID 37247226 · NCT03569293 (Measure Up 1) · Dermatitis, Atopic
  3. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
    Silverberg JI, Leshem YA, Calimlim BM, et al. · Curr Med Res Opin · 2023 · Derived
    PubMed: PMID 37691437 · NCT03568318 (AD Up) · Dermatitis, Atopic
  4. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
    Ponce-Bobadilla AV, Stodtmann S, Eckert D, et al. · Clin Pharmacokinet · 2023 · Derived
    PubMed: PMID 36571701 · NCT02819635 · Colitis, Ulcerative
  5. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    Parkes G, Ungaro RC, Danese S, et al. · J Gastroenterol · 2023 · Derived
    PubMed: PMID 37490069 · NCT02819635 · Colitis, Ulcerative
  6. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
    Panés J, Loftus EV, Higgins PDR, et al. · Inflamm Bowel Dis · 2023 · Derived
    PubMed: PMID 36645051 · NCT03653026 (U-Accomplish) · Colitis, Ulcerative
  7. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
    Paller AS, Ladizinski B, Mendes-Bastos P, et al. · JAMA Dermatol · 2023 · Derived
    PubMed: PMID 37043227 · NCT03569293 (Measure Up 1) · Dermatitis, Atopic
  8. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
    Mysler E, Tanaka Y, Kavanaugh A, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 36018230 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  9. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
    McInnes IB, Kato K, Magrey M, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 36243812 · NCT03104400 (SELECT - PsA 1) · Arthritis
  10. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
    Loftus EV, Colombel JF, Takeuchi K, et al. · Clin Gastroenterol Hepatol · 2023 · Derived
    PubMed: PMID 36464141 · NCT02819635 · Colitis, Ulcerative
  11. Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study.
    Kivitz A, Wells AF, Vargas JI, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 37199884 · NCT02049138 (BALANCE-EXTEND) · Arthritis, Rheumatoid
  12. Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2.
    Kiltz U, Kishimoto M, Walsh JA, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 37191738 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  13. Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study.
    Katoh N, Ohya Y, Murota H, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
    PubMed: PMID 36401761 · NCT03661138 (Rising Up) · Dermatitis, Atopic
  14. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
    Kakehasi AM, Radominski SC, Baravalle MD, et al. · Clin Rheumatol · 2023 · Derived
    PubMed: PMID 36715850 · NCT02675426 (SELECT-NEXT) · Arthritis, Rheumatoid
  15. Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study.
    Hayashi N, Ikeda M, Liu J, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
    PubMed: PMID 37356075 · NCT03661138 (Rising Up) · Dermatitis, Atopic
  16. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
    Fleischmann R, Curtis JR, Charles-Schoeman C, et al. · Ann Rheum Dis · 2023 · Derived
    PubMed: PMID 37308218 · NCT02706951 · Arthritis, Rheumatoid
  17. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.
    Danese S, Tran J, D'Haens G, et al. · Inflamm Bowel Dis · 2023 · Derived
    PubMed: PMID 36790041 · NCT03653026 (U-Accomplish) · Colitis, Ulcerative
  18. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials.
    Conaghan PG, Pavelka K, Hsieh SC, et al. · Rheumatol Adv Pract · 2023 · Derived
    PubMed: PMID 36794283 · NCT02706951 · Arthritis, Rheumatoid
  19. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Charles-Schoeman C, Choy E, McInnes IB, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 37945286 · NCT03178487 (SELECT-AXIS 1) · Spondylitis, Ankylosing
  20. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
    Burmester GR, Cohen SB, Winthrop KL, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 36754548 · NCT03104374 (SELECT - PsA 2) · Arthritis
  21. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X, van der Heijde D, Sieper J, et al. · Arthritis Res Ther · 2023 · Derived
    PubMed: PMID 37723577 · NCT02049138 (BALANCE-EXTEND) · Arthritis, Rheumatoid
  22. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X, Ranza R, Östör A, et al. · Arthritis Res Ther · 2023 · Derived
    PubMed: PMID 37038159 · NCT03104400 (SELECT - PsA 1) · Arthritis
  23. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Dermatitis, Atopic
  24. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Smolen JS, Landewé RBM, Bergstra SA, et al. · Ann Rheum Dis · 2023 · Background
    PubMed: PMID 36357155 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  25. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
    Ramiro S, Nikiphorou E, Sepriano A, et al. · Ann Rheum Dis · 2023 · Background
    PubMed: PMID 36270658 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  26. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Dermatitis, Atopic
  27. Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies.
    Feng Z, Kang G, Wang J, et al. · Biomed Pharmacother · 2023 · Background
    PubMed: PMID 36587559 · NCT06520397 · Crohn Disease

2022 (35 papers)

  1. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S, Vermeire S, Zhou W, et al. · Lancet · 2022 · Trial result
    PubMed: PMID 35644166 · NCT06780683 (EaseUpIBD) · Colitis, Ulcerative
  2. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Blauvelt A, Teixeira HD, Simpson EL, et al. · JAMA Dermatol · 2022 · Trial result
    PubMed: PMID 34347860 · NCT03738397 (Heads Up) · Dermatitis, Atopic
  3. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
    Yamaoka K, Tanaka Y, Kameda H, et al. · Drug Saf · 2022 · Derived
    PubMed: PMID 34041702 · NCT02706951 · Arthritis, Rheumatoid
  4. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study.
    Winthrop K, Vargas JI, Drescher E, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 35246470 · NCT02049138 (BALANCE-EXTEND) · Arthritis, Rheumatoid
  5. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D, Baraliakos X, Sieper J, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 35788492 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  6. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
    Strand V, Van den Bosch F, Ranza R, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34661885 · NCT03104374 (SELECT - PsA 2) · Arthritis
  7. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V, Tundia N, Bergman M, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 33590829 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  8. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V, Mease PJ, Soriano ER, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34636026 · NCT03104400 (SELECT - PsA 1) · Arthritis
  9. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
    Simpson EL, Papp KA, Blauvelt A, et al. · JAMA Dermatol · 2022 · Derived
    PubMed: PMID 35262646 · NCT03607422 · Dermatitis, Atopic
  10. Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS).
    Silverberg JI, Simpson EL, Calimlim BM, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 36333616 · NCT03568318 (AD Up) · Dermatitis, Atopic
  11. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
    Shimizu T, Kawashiri SY, Sato S, et al. · Medicine (Baltimore) · 2022 · Derived
    PubMed: PMID 35029189 · NCT05121298 (DOPPLER) · Arthritis, Rheumatoid
  12. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
    Peterfy CG, Strand V, Friedman A, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 34897366 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  13. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
    Nash P, Richette P, Gossec L, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 34864911 · NCT03104374 (SELECT - PsA 2) · Arthritis
  14. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
    Muensterman E, Engelhardt B, Gopalakrishnan S, et al. · Clin Transl Sci · 2022 · Derived
    PubMed: PMID 34464029 · NCT03104374 (SELECT - PsA 2) · Arthritis
  15. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
    Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. · J Am Acad Dermatol · 2022 · Derived
    PubMed: PMID 35714786 · NCT03607422 · Dermatitis, Atopic
  16. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
    Mease PJ, Lertratanakul A, Anderson JK, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 33272960 · NCT03104374 (SELECT - PsA 2) · Arthritis
  17. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
    Mease P, Kavanaugh A, Gladman D, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35606663 · NCT03104400 (SELECT - PsA 1) · Arthritis
  18. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
    Fleischmann RM, Blanco R, Hall S, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 33148701 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  19. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
    Deodhar A, van der Heijde D, Sieper J, et al. · Arthritis Rheumatol · 2022 · Derived
    PubMed: PMID 34196498 · NCT03178487 (SELECT-AXIS 1) · Spondylitis, Ankylosing
  20. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Deodhar A, Van den Bosch F, Poddubnyy D, et al. · Lancet · 2022 · Derived
    PubMed: PMID 35908570 · NCT04169373 (SELECT-AXIS 2) · Axial Spondyloarthritis
  21. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Cohen SB, van Vollenhoven RF, Winthrop KL, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 33115760 · NCT02706951 · Arthritis, Rheumatoid
  22. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR, Winthrop K, Blanco R, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34970731 · NCT03104400 (SELECT - PsA 1) · Arthritis
  23. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M, Tundia N, Martin N, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 35751108 · NCT03086343 · Arthritis, Rheumatoid
  24. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M, Buch MH, Tanaka Y, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 36125701 · NCT02706847 (SELECT-BEYOND) · Arthritis, Rheumatoid
  25. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Dermatitis, Atopic
  26. Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease.
    Stalgis C, Deepak P, Mehandru S, et al. · Gastroenterology · 2022 · Background
    PubMed: PMID 33961886 · NCT06520397 · Crohn Disease
  27. Breaking Through the Therapeutic Ceiling: What Will It Take?
    Raine T, Danese S · Gastroenterology · 2022 · Background
    PubMed: PMID 34995533 · NCT07442045 · Colitis, Ulcerative
  28. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
    Parigi TL, D'Amico F, Abreu MT, et al. · Lancet Gastroenterol Hepatol · 2022 · Background
    PubMed: PMID 35397241 · NCT06520397 · Crohn Disease
  29. Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn's Disease.
    Lee SD, Singla A, Harper J, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 34347103 · NCT06520397 · Crohn Disease
  30. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease.
    Haider SA, Yadav A, Perry C, et al. · Ther Adv Gastroenterol · 2022 · Background
    PubMed: PMID 33133239 · NCT06520397 · Crohn Disease
  31. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
    Fleischmann R, Mysler E, Bessette L, et al. · RMD Open · 2022 · Background
    PubMed: PMID 35121639 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  32. Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC.
    Coates LC, Garrood T, Gullick N, et al. · Rheumatology (Oxford) · 2022 · Background
    PubMed: PMID 35799375 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  33. GRAPPA Treatment Recommendations: 2021 Update.
    Coates LC, Corp N, van der Windt DA, et al. · J Rheumatol · 2022 · Background
    PubMed: PMID 35293339 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  34. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
    Bermejo F, Jiménez L, Algaba A, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 33528018 · NCT06520397 · Crohn Disease
  35. Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.
    Alayo QA, Khatiwada A, Patel A, et al. · Inflamm Bowel Dis · 2022 · Background
    PubMed: PMID 34037225 · NCT06520397 · Crohn Disease

2021 (20 papers)

  1. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V, Tundia N, Wells A, et al. · Rheumatology (Oxford) · 2021 · Derived
    PubMed: PMID 33313898 · NCT02706951 · Arthritis, Rheumatoid
  2. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Sandborn WJ, Ghosh S, Panes J, et al. · Gastroenterology · 2021 · Derived
    PubMed: PMID 32092309 · NCT02819635 · Colitis, Ulcerative
  3. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K, Teixeira HD, de Bruin-Weller M, et al. · Lancet · 2021 · Derived
    PubMed: PMID 34023009 · NCT03568318 (AD Up) · Dermatitis, Atopic
  4. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
    Mease PJ, Lertratanakul A, Papp KA, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 33913086 · NCT03104374 (SELECT - PsA 2) · Arthritis
  5. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    McInnes IB, Anderson JK, Magrey M, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33789011 · NCT03104400 (SELECT - PsA 1) · Arthritis
  6. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Kameda H, Takeuchi T, Yamaoka K, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 33407801 · NCT02720523 (SELECTSUNRISE) · Arthritis, Rheumatoid
  7. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW, McCourt C, Lima HC, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 33687069 · NCT03978520 (SLEek) · Lupus Erythematosus, Systemic
  8. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E, Teixeira HD, Simpson EL, et al. · Lancet · 2021 · Derived
    PubMed: PMID 34023008 · NCT03607422 · Dermatitis, Atopic
  9. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis.
    Bergman M, Tundia N, Yang M, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 34636000 · NCT02706951 · Arthritis, Rheumatoid
  10. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
    van Vollenhoven R, Takeuchi T, Pangan AL, et al. · Arthritis Rheumatol · 2021 · Background
    PubMed: PMID 32638504 · NCT02706873 (SELECT-EARLY) · Arthritis, Rheumatoid
  11. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.
    SCORE2 working group and ESC Cardiovascular risk collaboration · Eur Heart J · 2021 · Background
    PubMed: PMID 34120177 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  12. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.
    SCORE2-OP working group and ESC Cardiovascular risk collaboration · Eur Heart J · 2021 · Background
    PubMed: PMID 34120185 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  13. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.
    Schultheiss JPD, Mahmoud R, Louwers JM, et al. · Aliment Pharmacol Ther · 2021 · Background
    PubMed: PMID 34559428 · NCT06520397 · Crohn Disease
  14. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches.
    Privitera G, Pugliese D, Lopetuso LR, et al. · Ther Adv Gastroenterol · 2021 · Background
    PubMed: PMID 33995579 · NCT06520397 · Crohn Disease
  15. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Ollech JE, Normatov I, Peleg N, et al. · Clin Gastroenterol Hepatol · 2021 · Background
    PubMed: PMID 32109634 · NCT06520397 · Crohn Disease
  16. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
    Kameda H, Takeuchi T, Yamaoka K, et al. · Rheumatology (Oxford) · 2021 · Background
    PubMed: PMID 32277824 · NCT02720523 (SELECTSUNRISE) · Arthritis, Rheumatoid
  17. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
    Gold SL, Steinlauf AF · Gastroenterol Hepatol (N Y) · 2021 · Background
    PubMed: PMID 34602905 · NCT06520397 · Crohn Disease
  18. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
    Fenster M, Alayo QA, Khatiwada A, et al. · Clin Gastroenterol Hepatol · 2021 · Background
    PubMed: PMID 33068786 · NCT06520397 · Crohn Disease
  19. Breaking the therapeutic ceiling in drug development in ulcerative colitis.
    Alsoud D, Verstockt B, Fiocchi C, et al. · Lancet Gastroenterol Hepatol · 2021 · Background
    PubMed: PMID 34019798 · NCT07442045 · Colitis, Ulcerative
  20. T2 mapping of the sacroiliac joints in patients with axial spondyloarthritis.
    Albano D, Bignone R, Chianca V, et al. · Eur J Radiol · 2021 · Background
    PubMed: PMID 32911127 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2020 (13 papers)

  1. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E, Thaçi D, Pangan AL, et al. · J Allergy Clin Immunol · 2020 · Trial result
    PubMed: PMID 31786154 · NCT02925117 · Dermatitis, Atopic
  2. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V, Schiff M, Tundia N, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31791386 · NCT02706847 (SELECT-BEYOND) · Arthritis, Rheumatoid
  3. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V, Pope J, Tundia N, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31815649 · NCT02675426 (SELECT-NEXT) · Arthritis, Rheumatoid
  4. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.
    Nader A, Mohamed MF, Winzenborg I, et al. · Clin Pharmacol Ther · 2020 · Derived
    PubMed: PMID 31610021 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  5. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
    Mohamed MF, Klünder B, Camp HS, et al. · Clin Pharmacol Ther · 2020 · Derived
    PubMed: PMID 31194885 · NCT02066389 · Arthritis, Rheumatoid
  6. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
    Fleischmann RM, Genovese MC, Enejosa JV, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 31362993 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  7. Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis.
    Zabotti A, Sakellariou G, Tinazzi I, et al. · Ann Rheum Dis · 2020 · Background
    PubMed: PMID 32430315 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  8. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Yang E, Panaccione N, Whitmire N, et al. · Aliment Pharmacol Ther · 2020 · Background
    PubMed: PMID 32329532 · NCT06520397 · Crohn Disease
  9. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
    van der Heijde D, Song IH, Pangan AL, et al. · Lancet · 2020 · Background
    PubMed: PMID 31732180 · NCT03178487 (SELECT-AXIS 1) · Spondylitis, Ankylosing
  10. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A, Enejosa J, Pangan AL, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 33053283 · NCT03086343 · Arthritis, Rheumatoid
  11. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
    Gossec L, Baraliakos X, Kerschbaumer A, et al. · Ann Rheum Dis · 2020 · Background
    PubMed: PMID 32434812 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  12. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R, Pangan AL, Song IH, et al. · Arthritis Rheumatol · 2020 · Background
    PubMed: PMID 31287230 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  13. Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.
    Duarte-García A, Leung YY, Coates LC, et al. · J Rheumatol · 2020 · Background
    PubMed: PMID 30770518 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2019 (5 papers)

  1. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
    Klünder B, Mohamed MF, Othman AA, et al. · Clin Pharmacokinet · 2019 · Derived
    PubMed: PMID 29076110 · NCT02066389 · Arthritis, Rheumatoid
  2. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS, Pangan AL, Emery P, et al. · Lancet · 2019 · Background
    PubMed: PMID 31130260 · NCT02706951 · Arthritis, Rheumatoid
  3. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states.
    Machado PM, Landewé R, Heijde DV, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 29453216 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  4. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system.
    D'Agostino MA, Terslev L, Aegerter P, et al. · RMD Open · 2019 · Background
    PubMed: PMID 28948983 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  5. Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative.
    Balint PV, Terslev L, Aegerter P, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 30076154 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2018 (5 papers)

  1. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Singh S, George J, Boland BS, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 29370397 · NCT06520397 · Crohn Disease
  2. Acute severe ulcerative colitis: State of the art treatment.
    Gisbert JP, Chaparro M · Best Pract Res Clin Gastroenterol · 2018 · Background
    PubMed: PMID 30060940 · NCT07472309 · Colitis, Ulcerative
  3. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC, Fleischmann R, Combe B, et al. · Lancet · 2018 · Background
    PubMed: PMID 29908670 · NCT02706847 (SELECT-BEYOND) · Arthritis, Rheumatoid
  4. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR, Kremer JM, Van den Bosch F, et al. · Lancet · 2018 · Background
    PubMed: PMID 29908669 · NCT02675426 (SELECT-NEXT) · Arthritis, Rheumatoid
  5. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
    Adedokun OJ, Xu Z, Gasink C, et al. · Gastroenterology · 2018 · Background
    PubMed: PMID 29409871 · NCT06520397 · Crohn Disease

2017 (5 papers)

  1. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.
    Wolfe F, Clauw DJ, Fitzcharles MA, et al. · Semin Arthritis Rheum · 2017 · Background
    PubMed: PMID 27916278 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  2. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8.
    Moon SJ, Lee WY, Hwang JS, et al. · PLoS One · 2017 · Background
    PubMed: PMID 29095870 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  3. The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology.
    Möller I, Janta I, Backhaus M, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 28814430 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  4. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.
    Lambert RG, Bakker PA, van der Heijde D, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 26768408 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  5. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
    Genovese MC, Smolen JS, Weinblatt ME, et al. · Arthritis Rheumatol · 2017 · Background
    PubMed: PMID 27390150 · NCT02066389 · Arthritis, Rheumatoid

2016 (4 papers)

  1. Recommendations of the ESSR Arthritis Subcommittee for the Use of Magnetic Resonance Imaging in Musculoskeletal Rheumatic Diseases.
    Sudoł-Szopińska I, Jurik AG, Eshed I, et al. · Semin Musculoskelet Radiol · 2016 · Background
    PubMed: PMID 26583367 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  2. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
    Schoels MM, Aletaha D, Alasti F, et al. · Ann Rheum Dis · 2016 · Background
    PubMed: PMID 26269398 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  3. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Dermatitis, Atopic
  4. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
    Feagan BG, Sandborn WJ, Gasink C, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27959607 · NCT06520397 · Crohn Disease

2015 (2 papers)

  1. Power and color Doppler ultrasound settings for inflammatory flow: impact on scoring of disease activity in patients with rheumatoid arthritis.
    Torp-Pedersen S, Christensen R, Szkudlarek M, et al. · Arthritis Rheumatol · 2015 · Background
    PubMed: PMID 25370843 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  2. The skin in psoriasis: assessment and challenges.
    Oji V, Luger TA · Clin Exp Rheumatol · 2015 · Background
    PubMed: PMID 26472560 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2013 (2 papers)

  1. Reliability of a consensus-based ultrasound score for tenosynovitis in rheumatoid arthritis.
    Naredo E, D'Agostino MA, Wakefield RJ, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 22984169 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  2. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
    Feagan BG, Rutgeerts P, Sands BE, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23964932 · NCT07442045 · Colitis, Ulcerative

2011 (1 paper)

  1. Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level.
    Gutierrez M, Filippucci E, Salaffi F, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 21406459 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2010 (1 paper)

  1. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
    Aletaha D, Neogi T, Silman AJ, et al. · Arthritis Rheum · 2010 · Background
    PubMed: PMID 20872595 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2009 (2 papers)

  1. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.
    Rudwaleit M, van der Heijde D, Landewé R, et al. · Ann Rheum Dis · 2009 · Background
    PubMed: PMID 19297344 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid
  2. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index.
    Maksymowych WP, Mallon C, Morrow S, et al. · Ann Rheum Dis · 2009 · Background
    PubMed: PMID 18524792 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2007 (1 paper)

  1. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond.
    McGonagle D, Lories RJ, Tan AL, et al. · Arthritis Rheum · 2007 · Background
    PubMed: PMID 17665450 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2006 (1 paper)

  1. Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
    Taylor W, Gladman D, Helliwell P, et al. · Arthritis Rheum · 2006 · Background
    PubMed: PMID 16871531 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2005 (1 paper)

  1. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis.
    Maksymowych WP, Inman RD, Salonen D, et al. · Arthritis Rheum · 2005 · Background
    PubMed: PMID 16208659 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

2001 (1 paper)

  1. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.
    D'Haens G, Lemmens L, Geboes K, et al. · Gastroenterology · 2001 · Background
    PubMed: PMID 11313301 · NCT07546097

1995 (1 paper)

  1. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
    Prevoo ML, van 't Hof MA, Kuper HH, et al. · Arthritis Rheum · 1995 · Background
    PubMed: PMID 7818570 · NCT06630715 (OPTIMA) · Arthritis, Rheumatoid

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).